Free Trial

Stryker (SYK) Competitors

$342.64
+1.29 (+0.38%)
(As of 06/21/2024 09:00 PM ET)

SYK vs. ABT, ISRG, BSX, MDT, BDX, EW, DXCM, IDXX, RMD, and STE

Should you be buying Stryker stock or one of its competitors? The main competitors of Stryker include Abbott Laboratories (ABT), Intuitive Surgical (ISRG), Boston Scientific (BSX), Medtronic (MDT), Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), and STERIS (STE). These companies are all part of the "health care equipment" industry.

Stryker vs.

Stryker (NYSE:SYK) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, community ranking, institutional ownership, profitability, dividends and analyst recommendations.

Abbott Laboratories received 31 more outperform votes than Stryker when rated by MarketBeat users. Likewise, 69.67% of users gave Abbott Laboratories an outperform vote while only 64.45% of users gave Stryker an outperform vote.

CompanyUnderperformOutperform
StrykerOutperform Votes
890
64.45%
Underperform Votes
491
35.55%
Abbott LaboratoriesOutperform Votes
921
69.67%
Underperform Votes
401
30.33%

Stryker pays an annual dividend of $3.20 per share and has a dividend yield of 0.9%. Abbott Laboratories pays an annual dividend of $2.20 per share and has a dividend yield of 2.1%. Stryker pays out 36.5% of its earnings in the form of a dividend. Abbott Laboratories pays out 68.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

77.1% of Stryker shares are held by institutional investors. Comparatively, 75.2% of Abbott Laboratories shares are held by institutional investors. 5.9% of Stryker shares are held by company insiders. Comparatively, 1.1% of Abbott Laboratories shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Stryker has a net margin of 16.03% compared to Abbott Laboratories' net margin of 13.96%. Stryker's return on equity of 23.05% beat Abbott Laboratories' return on equity.

Company Net Margins Return on Equity Return on Assets
Stryker16.03% 23.05% 10.88%
Abbott Laboratories 13.96%20.18%10.60%

Stryker currently has a consensus target price of $370.58, suggesting a potential upside of 8.15%. Abbott Laboratories has a consensus target price of $120.64, suggesting a potential upside of 14.11%. Given Abbott Laboratories' higher probable upside, analysts clearly believe Abbott Laboratories is more favorable than Stryker.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Stryker
0 Sell rating(s)
4 Hold rating(s)
15 Buy rating(s)
0 Strong Buy rating(s)
2.79
Abbott Laboratories
0 Sell rating(s)
3 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.70

In the previous week, Stryker had 1 more articles in the media than Abbott Laboratories. MarketBeat recorded 10 mentions for Stryker and 9 mentions for Abbott Laboratories. Stryker's average media sentiment score of 1.17 beat Abbott Laboratories' score of 1.11 indicating that Stryker is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Stryker
7 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Abbott Laboratories
8 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Stryker has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500.

Abbott Laboratories has higher revenue and earnings than Stryker. Abbott Laboratories is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Stryker$20.50B6.37$3.17B$8.7639.11
Abbott Laboratories$40.11B4.59$5.72B$3.2132.93

Summary

Stryker beats Abbott Laboratories on 14 of the 20 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SYK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SYK vs. The Competition

MetricStrykerSurgical & medical instruments IndustryMedical SectorNYSE Exchange
Market Cap$130.53B$3.79B$4.94B$17.60B
Dividend Yield0.94%1.81%5.25%3.62%
P/E Ratio39.118.42119.2721.13
Price / Sales6.3772.992,218.0014.35
Price / Cash25.4646.8932.5819.17
Price / Book7.004.124.754.56
Net Income$3.17B$4.30M$105.56M$971.75M
7 Day Performance-0.60%-0.13%116.60%1.88%
1 Month Performance2.12%-0.90%115.17%-0.50%
1 Year Performance15.03%-18.02%122.64%11.76%

Stryker Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ABT
Abbott Laboratories
4.9794 of 5 stars
$103.99
+0.5%
$120.64
+16.0%
-2.2%$180.90B$40.11B32.40114,000Positive News
ISRG
Intuitive Surgical
4.5575 of 5 stars
$435.00
+1.2%
$403.67
-7.2%
+32.2%$154.29B$7.32B78.5213,676Positive News
BSX
Boston Scientific
4.0939 of 5 stars
$76.34
+0.2%
$76.70
+0.5%
+44.0%$112.00B$14.24B64.1548,000Analyst Upgrade
MDT
Medtronic
4.9524 of 5 stars
$79.75
-0.3%
$93.00
+16.6%
-6.7%$105.89B$32.36B29.0095,000
BDX
Becton, Dickinson and Company
4.7074 of 5 stars
$233.74
+0.4%
$280.17
+19.9%
-7.1%$67.55B$19.37B51.4873,000Positive News
EW
Edwards Lifesciences
4.3717 of 5 stars
$88.53
+1.9%
$95.06
+7.4%
+0.6%$53.35B$6.00B38.1619,800Positive News
DXCM
DexCom
4.8716 of 5 stars
$116.64
+0.1%
$140.94
+20.8%
-8.0%$46.39B$3.62B75.259,600
IDXX
IDEXX Laboratories
4.165 of 5 stars
$503.60
-0.1%
$580.38
+15.2%
+1.6%$41.59B$3.66B48.7511,000Positive News
RMD
ResMed
4.498 of 5 stars
$212.27
+0.9%
$202.80
-4.5%
-4.4%$31.18B$4.22B32.6110,140Positive News
STE
STERIS
4.658 of 5 stars
$216.50
+0.2%
$241.60
+11.6%
+3.5%$21.40B$5.14B56.6818,179Positive News

Related Companies and Tools

This page (NYSE:SYK) was last updated on 6/24/2024 by MarketBeat.com Staff

From Our Partners